Korea Research Institute of Bioscience and Biotechnology

Leadbio, Inc.

Angiolab, Inc.

Bioholdings Co., Ltd.

Jeong-Yoon Kim

Hyun Ah Kang

Min-Young Kim

Sang-Ki Rhee

Eun-Kyu Park

Doo-Byoung Oh

Hyun-Ah Kang

Jeong-Nam Park

Yunkyoung Song

Min-Jeong Sohn

Jae-Young Chang

The present invention relates to a novel YlMPO1 gene which plays an important role in mannosylphosphorylation of an industrial yeastand to a method for preparing a host system capable of producing recombinant glycoproteins free of mannosylphosphate by disruption of the gene. The mannosylphosphorylation is suppressed by the disruption of YlMPO1 gene according to the present invention, thereby achieving humanization of glycosylation pathway of

YLMPO1 gene derived from yarrowia lipolytica and a process for preparing a glycoprotein not being mannosylphosphorylated by using a mutated yarrowia lipolytica in which YLMPO1 gene is disrupted

The present invention relates to a nucleic acid molecule comprising the HpYPS1 gene encodingyapsin1, a polypeptide encoded by the nucleic acid molecule, amutant strain having reduced yapsin activity by mutation of the HpYPS gene encodingyapsin1, a recombinantstrain expressing a foreign protein produced by introducing a gene encoding the foreign protein into themutant strain, and a process for preparing a foreign protein comprising culturing the recombinantstrain under conditions to express the foreign protein and isolating the foreign protein from the culture.

[object Object]

The present invention provides a human serum albumin-TIMP2 fusion protein having the amino acid sequence set forth in SEQ ID NO. 10, a polynucleotide encoding the same and a vector comprising the polynucleotide, a host cell transformed with the vector, a method for producing the human serum albumin-TIMP2 fusion protein and a pharmaceutical composition comprising the human serum albumin-TIMP2 fusion protein. The human serum albumin-TIMP2 fusion protein is stable and retains the activity of TIMP2, thus it can be used as a pharmaceutical composition to treat diseases related to angiogenesis and/or metastasis of cancer cells.

Human serum albumin-TIMP2 fusion protein, a polynucleotide encoding the same and a method of producing the human serum albumin-TIMP2 fusion protein

Growing community of inventors

Daejeon, South Korea

Jeong-Yoon Kim